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Abstract
Here we have characterized perthamide C, a cyclopeptide from a Solomon Lithistid sponge Theonella swinhoei, which
displays an anti-inflammatory/immunomodulatory activity. The study has been performed using the carragenan-induced
mouse paw edema that displays an early (0–6 h) and a late phase (24–96 h). Perthamide C significantly inhibits neutrophils
infiltration in tissue both in the early and late phases. This effect was coupled to a reduced expression of the endothelial
nitric oxide synthase (eNOS) in the early phase while cyclooxygenase-1 and 2 (COX-1, COX-2), and inducible NOS (iNOS)
expression were unaffected. In the late phase perthamide C reduced expression of both NOS isoforms without affecting
COXs expression. This peculiar selectivity toward the two enzymes deputed to produce NO lead us to investigate on a
possible action of perthamide C on lymphocytes infiltration and activation. We found that perthamide C inhibited the
proliferation of peripheral lymphocytes, and that this effect was secondary to its metabolic activation in vivo. Indeed, in vitro
perthamide C did not inhibit proliferation as opposite to its metabolite perthamide H. In conclusion, perthamide C
selectively interferes with NO generation triggered by either eNOS or iNOS without affecting either COX-1 or COX-2. This in
turn leads to modulation of the inflammatory response through a reduction of vascular permeability, neutrophil infiltration
as well as lymphocyte proliferation.
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Introduction
Within marine invertebrates, sponges have developed a highly
complex immune system associated to the capacity to produce
efficiently secondary metabolites as a defence mechanism.
Moreover, sponges have provided a number of compounds
exhibiting anti-inflammatory activity [1]. The cellular targets of
these drugs are often different from those of non-steroidal anti-
inflammatory drugs (mainly cyclooxygenase-1 or -2 inhibition) and
in some cases relate to the inhibition of inflammatory gene
transcription.
In our studies on bioactive compounds from sponges collected
at Solomon Islands, [2] we found a single specimen of the sponge
Theonella swinhoei, (Order Lithistida, Class Demospongia), as an
extraordinary source of new metabolites. Analysis of the polar
extracts afforded anti-inflammatory peptides such as the large
library of perthamide C derivatives [3–6] and solomonamides A–
B, [7] and anti-inflammatory sulfated sterols, solomonsterols A
and B [8], potent agonists of the human nuclear receptor and
xenobiotic sensor, pregnane-X-receptor (PXR) and new leads in
the treatment of immune-driven inflammatory bowel diseases [9].
From a structural point of view, perthamide C has a peculiar
unprecedented primary structure that comprises a 25-membered
macrocycle with 6 out of the 8 residues constituted by unusual
amino acids: c-methylproline, Nd-carbamoyl-b-OSO3Asparagine,
o-tyrosine, d-ABU, O-methylthreonine, and the b-amino acid
AHMHA (3-amino-2-hydroxy-6-methylheptanoic acid). Acute
inflammatory response is characterized by an increase in vascular
permeability and cellular infiltration leading to oedema formation
as a result of extravasation of fluid and proteins, and accumulation
of leukocytes at the inflammatory site. Following these changes,
many other mechanisms are activated, contributing to the
amplification of the inflammatory response and tissue damage,
leading to the development of a more complex ‘scenario’ e.g. the
chronic inflammatory reaction. Recently we have shown that
perthamide C, among the different derivatives screened, signifi-
cantly inhibited the inflammatory reaction in vivo [3]. Since
perthamide C given systemically resulted active at very low dose
e.g 0.3 mg/kg ip we have investigated in details the mechanism of
this powerful anti-inflammatory activity.
Materials and Methods
Induction of edema in mouse paw
Male Swiss (CD-1; Harlan, Italy) weighing .30 g were divided
into groups (n = 6 each group) and lightly anaesthetized with
isoflurane. Each group of animals received subplantar injection of
50 ml of l-carrageenan 1% (w/v) or 50 ml of saline in the left hind
paw. Paw volume was measured by using an hydropletismometer
specially modified for small volumes (Ugo Basile, Comerio, Italy)
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immediately before the subplantar injection and 2, 4, 6, 24, 48, 72
and 96 h thereafter. The same operator always performed the
double-blind assessment of paw volume. The increase in paw
volume was calculated as the difference between the paw volume
measured at each time point and the basal paw edema. Each
group of animals received 100 ml of perthamide C (0.3 mg/kg), or
vehicle (polyethilenglycole, PEG) given i.p immediately before the
injection of l-carrageenan and 24 h thereafter. In a separate set of
experiments dexamethasone (4 mg/kg) or vehicle (saline) were
administered i.p.1 h prior l-carrageenan injection and 24 h
thereafter.
All procedures were performed according to Italian ministerial
authorization (DL 116/92) and European regulations on the
protection of animals used for experimental and other scientific
purposes. The study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Italian Ministry of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Naples Federico II (Protocol
Number: 2009/0047185). The paw edema was performed under
enflurane anesthesia, and all efforts were made to minimize
suffering.
Myeloperoxidase (MPO) measurement in injected paws
Mice from different groups were euthanized with CO2 at
different time points from l-carrageenan or vehicle injection. Paws
were cut, weighed and homogenized in 1 ml of hexadecyltri-
methylammonium bromide (HTAB) buffer on ice by using a
Polytron homogenizer (two cycles of 10 sec at maximum speed).
After centrifugation at 10,000 rpm for 2 min, supernatant
fractions were assayed for MPO activity as an estimate of cellular
migration according to the method described in Posadas et al.,
2004. Briefly, samples (20 ml) were mixed with phosphate buffer
(180 ml) containing 1 mM O-dianisidine dihydrochloride and
0.001% hydrogen peroxide in a microtiter plate. Absorbance
was measured at 450 nm, performing three readings at 30-s
intervals. Calculation of MPO units was evaluated considering
that 1 U MPO = 1 mmol H2O2 split and 1 mmol H2O2 gives a
change in absorbance of 1.1361022 (change in absorbance = nm
min).
Western blot analysis
Paws were harvested from different groups of mice at different
time points after l-carrageenan or vehicle injection, and
homogenized in modified RIPA buffer (Tris HCl 50 mM,
pH 7.4, triton 1%, Na-deoxycholate 0.25%, NaCl 150 mM,
EDTA 1 mM, phenylmethanesulphonylfluoride 1 mM, aprotinin
Figure 1. Perthamide C reduces MPO activity in both phases of oedema. Paws were harvested at different time points 2-4-6 h (A) and 24-48-
72-96 h (B) from each group of animals and processed in order to measure MPO activity. Values are expressed as mean6s.e.m. (n=4–6 paws for each
time point). *P,0.05 **P,0.01, ***P,0.001 vs S (saline), u P,0.05, uu P,0.01 vs vehicle.
doi:10.1371/journal.pone.0057801.g001
Perthamide C Immunomodulating Activity
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10 mg/ml, leupeptin 20 mM, NaF 50 mM) using a polytron
homogenizer (two cycles of 10 sec at maximum speed) on ice.
After centrifugation at 12,000 rpm for 15 min, protein concen-
tration was determined by Bradford assay using BSA as standard
(Bio-Rad Laboratories, Milan, Italy). 40 mg of the denatured
proteins were separated on 10% SDS/PAGE and transferred to a
PVDF membrane. Membranes were blocked in PBS-tween 20
(0.1%, v/v) containing 3% non fat dry milk for 1 hour at room
temperature, and then incubated with anti-COX1 (1:1000), anti
COX-2 (1:1000), anti-eNOS (1:1000) or anti-iNOS (1:500)
overnight at 4uC. The filters were washed with PBS-tween 20
(0.1%, v/v) extensively for 30 min, before incubation, for 2 hours
at 4uC, with the secondary antibody (1:5000) conjugated with
horseradish peroxidase antimouse IgG. The membranes were then
washed and immunoreactive bands were visualized using an
Enhanced Chemiluminescence Substrate (ECL; Amersham Phar-
macia Biotech, San Diego, CA, USA).
Preparation of cell suspension
Cell suspension was obtained as previously described [10].
Briefly, peripheral lymph nodes (PLN) (axillary, brachial, inguinal,
cervical and mesenteric) were harvested from different groups of
animals and at different time points from l-carrageenan injection.
Cells were pooled and prepared as single cell suspensions, by
passing through a Nitex sieve (Cadisch Precision Meshes,
London,UK) using a syringe plunger, and washed in sterile
RPMI-1640 (Invitrogen Life Technologies, Paisley, UK). Mono-
cytes were obtained by separation with Histopaque 10771 (Sigma,
Milan, Italy). The cell suspensions obtained were used for the
evaluation of the proliferative response to Concanavalin A (Con
A).
Proliferation assay
The MTT colorimetric assay, based on the ability of viable cells
to reduce the yellow MTT (3-[4,5- dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide) salt to the blue MTT formazan
product, was used to assess lymphocytes proliferation in vitro.
Preliminary experiments determined that lymphocytes number
and absorbance (570 nm) formed a linear relationship thereby
providing a reliable assay for measurement of cell proliferation.
PLN lymphocytes obtained from mice of each study group, were
dispensed into 96-well plates at a density of 26106 cells per well in
Figure 2. Western blot analysis of eNOS and COX-1 in the early phase of the paw edema. Expression of eNOS and COX-1 (A) were
evaluated in total tissue extracts from paw homogenates obtained from mice treated with perthamide C, vehicle or saline at 2, 4 and 6 h following l-
carragenan injection (n = 4 paws for each treatment and time point). In panel B and C are shown the relative densitometric analysis uP,0.05,
uuP,0.01 vs vehicle. Image is representative of three separate experiments.
doi:10.1371/journal.pone.0057801.g002
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RPMI media containing streptomycin/penicillin (1%), sodium
pyruvate (0.1%), 2-mercaptoethanol (0.1%) and foetal calf serum
(10%) in a final volume of 150 ml and kept in an incubator at 37uC
and in an atmosphere of, 5% CO2+95% air., To induce T cells
proliferative responses cells were pulsed with Con A (5 mg/ml) for
72 h. In the last 4 h of incubation, 25 ml MTT reagent was added
to each well. This step was followed by the addition of detergent
reagent (100 ml per well) for 2 h to enable complete solubilisation
of formazan product (plates kept in the dark). The absorbance of
the samples was then measured using a microplate reader at
570 nm. Each treatment/assay was based on n = 6 replicate
samples.
In a separate set of experiment we tested the biological activity
of perthamide C on lymphocytes obtained from mice of the na¨ive
group. In this set of experiments, cells were pulsed for 72 h with
Con A (5 mg/ml) in presence or absence of different concentra-
tions (3-10-30 mM) of perthamide C.
Sample preparation for mass spectrometry-based
detection of perthamide C and H in mouse plasma
Plasma samples were collected from mice of each group at
different time points after perthamide C administration. The
clean-up procedure of plasma was performed by solid-phase
extraction as previously described [11]. The Waters Sep-Pak Vac
tC18 cartridges (50 mg) were initially washed with 2 ml ACN and
then pre-conditioned with 5 ml of H2O containing 0.05%TFA
and 2% HCOOH. 100 ml of ice plasma were put at 37 uC for
15 min and then diluted at 2 ml with H2O. Each sample was then
applied onto the cartridge, the cartridge was washed with 2 ml of
H2O containing 0.05% TFA and 2% HCOOH and the analytes
were eluted using 100% ACN containing 0.05% TFA and 2%
HCOOH. The eluted substances perthamides C and H were dried
and the residues were dissolved in 100 ml of 100% ACN
containing 0.05% TFA and 2% HCOOH. This procedure has
been repeated 3 times for each of mice plasma at 0, 1, 4, 16 and
24 h, after each perthamide C administration.
Figure 3. Western blot analysis of eNOS and iNOS in the late phase of the paw edema. Expression of eNOS (A) and iNOS (B) were
evaluated in paws homogenates obtained from mice treated with perthamide C, vehicle or saline at 24, 48, 72, 96 h following l-carragenan injection.
(n = 4 paws for each treatment and time point)**P,0.01vs saline, u P,0.05, uu P,0.01, uuu P,0.001 vs vehicle. Image is representative of three
separate experiments.
doi:10.1371/journal.pone.0057801.g003
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Finally, in order to measure the recovery rate of extraction, the
same procedure has also been carried out on blank samples spiked
with both perthamides C and H and at different concentrations for
3 times; the recovery rate of the procedure is around 90%.
RP-HPLC-MS/MS method for detection of perthamide C
(1) and H (2) in mouse plasma
25 ml of the extracts were injected into the HPLC–MS system
LTQ XL ThermoScientific equipped with Accelera 600 Pump
and Accelera AutoSampler system. The mixture was separated on
a Jupiter 5 m C18 column from Phenomenex (15062.00 mm)
using a mobile phase consisted on H2O-0.05% TFA-2% HCOOH
(eluent A) and ACN-0.05% TFA-2% HCOOH (eluent B). The
eluents were linearly changed from 10% B to 70% B within
14 min; the columns flow rate was set at 200 ml/min. The mass-
spectrometer was set to operate with an ESI ionization source in
positive and negative mode. The capillary temperature was kept at
320 uC, the sheath gas flow rate and the auxiliary flow rate were
set at 10 and 5, respectively. Instrument optimization was
performed by direct infusion and manual tuning. Detection of
perthamides C and H was performed using the selected reaction-
monitoring mode (SRM). The transition of the deprotonated
perthamide C molecule to its corresponding product ions was
recorded at m/z 1066.5R1023.5 (-CONH) and m/z
1068.5R1025.5 (-CONH) and the transition of the protonated
perthamide H molecule to its corresponding product ions was
recorded at m/z 988.5R971.5 (-NH3). The collision energy used
was set at 35.
As standard for calculating the relative percentage of these
metabolites, several runs of samples containing perthamide C
alone, perthamide H alone or the same concentration of
perthamides C and H upon clean up procedure were also
performed.
Sponge material and isolation of perthamides C and H
Theonella swinhoei (order Lithistida, family Theonellidae) was
collected on the barrier reef of Vangunu Island, Solomon Islands,
in July 2004. Authorization to collection and exportation of sponge
samples was released by Fisheries Department of Solomon Islands
Government to IRD (Institut de Recherche pour le De`veloppe-
ment, Polynesian Research Center on Island Biodiversity, BP529,
98713 Papeete, Tahiti, French Polynesia) in the frame of a
research project entitled: ‘Coral Reef Initiative in The South
Pacific’ (CRISP) ‘Biodiversite´ et substances marines actives’, volet
Figure 4. Western blot analysis of COX-1 and COX-2 in the late phase of the paw edema. Expression of COX-1 (A) and COX-2 (B) were
evaluated in paws homogenates obtained from mice treated with perthamide C, vehicle or saline at 24, 48, 72, 96 h following l-carrageenan
injection. (n = 4 paws for each treatment and time point) *P,0.05 **P,0.01 vs saline. Image is representative of three separate experiments.
doi:10.1371/journal.pone.0057801.g004
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Mole´cules actives, soutenu par l9Agence Franc¸aise pour le
De´veloppement’, authorization IRD–AFDCZZ3012-02U. The
sponge lyophilized material was kindly provided by Dr. Cecile
Debitus, IRD. The sponge is not on the endangered and protected
species list (CITES list, www.cites.org) and no specific permits
were required for the described field studies. Taxonomic
Figure 5. Proliferation assays on lymphocytes. Lymphocytes were obtained from PLN of control (vehicle) or perthamide C treated mice 4 h, 8 h
or 96 h after l-carrageenan edema induction. Values are means6SEM of three separate experiments with n= 5–6 mice. ***P,0.001 vs Naive+Con A;
uuuP,0.001 vs CTL+Con A.
doi:10.1371/journal.pone.0057801.g005
Figure 6. Proliferation assays on lymphocytes harvested from na¨ive mice. Perthamide H significantly inhibited, in a dose-dependent
manner, Con A-induced proliferation of lymphocytes. Values are means6SEM of three separate experiments with n = 5–6 mice. ***P,0.001 vs basal
(Bas);uuuP,0.001 vs Con A.
doi:10.1371/journal.pone.0057801.g006
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identification was performed by Dr John Hooper of Queensland
Museum, Brisbane, Australia, where specimens are deposited
under the accession number G3122662. Identity of perthamide C
and H was established by comparison of their RM and mass data
with those previously reported [6].
Evaluation of ulcerogenic effect of perthamide C
Mice were randomly divided in three groups (n = 3 for each
group) and deprived of food, but allowed to drink water at libitum,
for 16 hours. Administration of perthamide C (0.3 mg/kg i.p.)
indomethacin (20 mg/kg per os, 100 ml), or vehicle (PEG) were
then performed. Indomethacin was used as positive control. Three
hours after the drugs administration, mice were euthanized by an
overdose of anesthetic and stomachs were harvested and washed in
saline. A longitudinal incision along the greater curvature was
performed and the stomachs were inverted over the index finger.
Lesions were blindly evaluated macroscopically with an arbitrary
score as follows:
0 = healthy; 1 = hyperemic
2 = lesions without blood
3 lesions with blood
Drugs and Reagents
Bradford reagent was obtained from Bio-Rad (Bio-Rad
laboratories, Segrate, Milan, Italy). The antibodies against
COX-2, eNOS and iNOS were purchased from BD Transduction
laboratories (U.S.A.). The antibody against COX-1 was from
Santa Cruz Biotechnology, Inc (Milan, Italy). All other reagents
and compound used were obtained from Sigma-Aldrich (Milan,
Italy).
Statistical analysis
Results were expressed as mean6s.e.m. The level of statistical
significance was determined by one way ANOVA followed by
Dunnett’s test for multiple comparisons or t-test analysis where
appropriate, using GraphPad Prism software (GraphPad Software
Inc., San Diego, CA). Differences were considered statistically
significant when p was less than 0.05. Each sample was processed
at least in triplicate.
Results
Perthamide C inhibits MPO activity in carragenan-
induced mouse paw edema
We have previously shown, that systemic administration of
perthamide C significantly reduced both the early (0–6 h) and the
late phase (24–96 h) of l-carrageenan-induced paw edema
displaying a dose-dependent (0.1, 0.3 and 1 mg/kg, i.p.) anti-
inflammatory activity that reached almost 60% of oedema
inhibition at the dose of 0.3 mg/kg [6].
To clarify the mechanism/s of action of perthamide C we firstly
evaluated the MPO activity, as an index of neutrophil infiltration
in response to l-carrageenan injection. As shown in Figure1 A and
B, l-carrageenan injection induced a significative increase in
neutrophil infiltration into the mouse paw. Administration of
perthamide C reduced MPO activity as compared to vehicle
Figure 7. Chemical structure and LCMS runs of perthamide C and H. Panel A shows the chemical structure of perthamide C and H. Panel B
shows one of the LCMS runs for detecting perthamides C and H in mice plasma samples using the selected reaction-monitoring mode (SRM). The
peak at rt of 12.25 min corresponds to deprotonated perthamide C, the peak at rt of 12.33 min corresponds to protonated perthamide H, the peak at
rt of 22.62 min corresponds to protonated perthamide C. Panel C shows the % of pertamides C and H detected by LCMS in mice plasma samples after
0, 1, 4, 16 and 24 h from each perthamide C administration.
doi:10.1371/journal.pone.0057801.g007
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group and this effect resulted statistically significant at 6 and 24 h
after l-carrageenan injection, when MPO activity reaches its
highest levels (Figure1 A and B) [12].
Perthamide C reduces the expression of NOS but not
COX isoforms
Next we evaluated if perthamide C administration was able to
modify the expression levels of the constitutive enzymes eNOS and
COX-1 as well as of their respective inducible isoforms, iNOS and
COX-2. Thus, we performed western blot analysis on paw
homogenates obtained from each groups of animals. As shown in
figure 2 (panels A, B, C), during the early phase of edema both
eNOS and COX-1 were expressed in total extracts obtained from
saline- and l-carrageenan-injected paw homogenates (Figure 2A
and B). As expected, their inducible isoforms, iNOS and COX-2,
were not detectable in this timeframe (data not shown). Systemic
administration of perthamide C significantly reduced eNOS
expression after 2 h and 4 h from l-carrageenan injection
(Figure 2A and B), while COX-1 expression was not modified
by perthamide C treatment all throughout the early phase of
edema (Figure 2A and C).
We observed a different ‘scenario’ in the late phase of oedema
following administration of perthamide C. In fact, as shown in
figure 3 (panels A, B), systemic administration of perthamide C
significantly reduced the expression of both NOS isoforms while it
did not inhibit either COX-1 or COX-2 (Figure 4A and B).
Perthamide C inhibits Con-A induced cellular
proliferation
Injection of l-carrageenan in the hind paw causes activation
and proliferation of T cells in the draining lymph nodes.
Proliferation assays showed that lymphocytes harvested from
control mice (mice receiving only l-carrageenan) responded to
Con A stimulation as compared to cells obtained from vehicle
group (Figure 5). Treatment of mice in vivo with perthamide C
(0.3 mg/Kg/i.p.) significantly suppressed the proliferative re-
sponse to Con A of lymphocytes at all time points considered (4-
48-96 hrs) as compared to the control group (Figure 5). Dexa-
methasone (4 mg/kg) was used as reference drug (Figure 5).
In a separate set of experiment we tested the biological activity
of perthamide C in vitro on lymphocytes obtained from na¨ive mice.
Cells were pulsed for 72 h with Con A (5 mg/ml) in presence or
absence of different concentrations (3-10-30 mM) of perthamide C
(data not shown). Surprisingly, in contrast with the ex-vivo
experiments, perthamide C added to the cells in vitro, did not
modify Con A-induced cellular proliferation at any of the
concentrations tested. Thus we hypothesized that the molecule
we were using in vitro was probably subjected, in vivo, to a metabolic
activation, most likely at the sulfate group on the Nd-carbamoyl-b-
OSO3Asparagine unit, thus acting as a pro-drug. To prove this
hypothesis, we decided to test the effect of the desulfated
perthamide C derivative, perthamide H, recently isolated by our
research group from a deep re-investigation of the polar extracts of
Theonella swinhoei [6]. As we hypothesized, the elimination of the
sulfate group in perthamide C led to the active form of the
molecule that was able to inhibit also in vitro and in a
concentration-dependent manner, the Con A-induced prolifera-
tion of lymphocytes from na¨ive mice (Figure 6).
Perthamide C is converted in vivo in its desulfated
derivative, perthamide H
In order to measure the relative levels of perthamide C and H in
mice plasma upon different time from each perthamide C
Figure 8. Perthamide C does not possess ulcerogenic action. Blindly arbitrary score was assessed as follows: 0 = healthy; 1 = hyperemic;
2 = lesions without blood; 3 lesions with blood; n = 3 for each group indomethacin was used as a control ulcerogenic drug. Pictures are representative
of three different animals for each group of treatment.
doi:10.1371/journal.pone.0057801.g008
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administration, we resorted to a selective quantification of these
metabolites by RP-HPLC-MSMS analysis. Plasma samples of
three different mice collected at 1, 4 and 16 and 24 h from each
perthamide C administration have been pre-cleaned by solid-
phase extraction and the fractions eluted at 100% ACN have been
submitted to RP-HPLC-MSMS runs operating in selected
reaction monitoring (SRM) mode. Perthamide C shows two
chromatographic peaks respectively at 12.25 min (MH2 at
1066.5) and at 22.50 min (MH+ at 1068.5); this behaviour was
probably due to the charge state of Nd-carbamoyl-b-OSO3Aspar-
agine residue (Figure 7A and B). Perthamide H retention time is
12.33 min and its MH+ is 988.50 as expected (Figure 7A and B).
The area of these three peaks has been integrated in each run and
the results has been reported as relative percentage of the two
metabolites (Figure 7C). At a starting point, 100% of perthamide
C has been arbitrary set.
It’s noteworthy that, upon 1 h from each perthamide C
administration, around 35% of this pro-drug has been desulfated
giving rise to its active derivative perthamide H whereas, after 4,
16 and 24 h from each administration, decreasing levels of
perthamide C and perthamide H have been detected.
Perthamide C does not exert ulcerogenic action
In order to verify if perthamide C treatment could induce
gastric lesions, a standard animal model for ulcerogenic activity
was performed. As shown in Figure 8, perthamide C, at the dose
that exerts anti-inflammatory action, did not induce any damage
to gastric mucosa. Indeed, the score obtained from perthamide C
treatment group (Figure 8B) was comparable to one obtained from
vehicle group (Figure 8A). Conversely, administration of NSAID
drug indomethacin, used as positive control, induced a massive
ulcerogenic action (Figure 8C), as highlighted by the high score
reached.
Discussion
In the present study we have investigated, in details, the
molecular mechanism of the anti-inflammatory activity exhibited
by perthamide C [3]. We have used to address this issue the l-
carrageenan mouse paw edema since due to its, sub-chronic
nature it has allowed us to dissect the early event triggered within
few hours from those that are deployed later within 3–4 days. In
fact, the l-carrageenan induced mouse paw edema as opposite to
rats, produces a biphasic edema. In the first phase, which
developed up to 6 h, edema is of low intensity, while in the
second phase, after 24 h, edema is more pronounced and peaks at
72 h after l-carrageenan injection [10,12,13]. Another important
feature of this model is that, as the inflammation progresses, an
increasing number of T cells infiltrate the draining lymph nodes of
the l-carrageenan-injected paws [10] thereby this model is also
reminiscent of a typical type III immune reaction. In this reaction
regional lymph nodes are the source of effector T cells that are
postulated to extravasate at the site of antigen challenge and in
turn, recruit and activate a variety of nonspecific inflammatory
cells [14]. Perthamide C significantly inhibited the myeloperox-
idase activity, a marker of neutrophil infiltration in tissue, in the
early phase of the inflammatory reaction. This effect was coupled
to a reduced expression of the endothelial nitric oxide synthase
(eNOS) while COX-1, iNOS and COX-2 expression were
unaffected. Thus, perthamide C inhibitory effect in vivo is fast on
onset and its action is possibly linked to modulation of eNOS-
derived NO. This feature well fit with the finding that, in this
model, the increase in vascular permeability in the early phase is
dependent upon eNOS-derived NO [15]. Most likely the
modulation of perthamide C operated on eNOS is linked to its
ability to bind hsp90 [16]. Indeed, hsp90 is instrumental for eNOS
activation as elegantly demonstrated in the paper by Garcı´a-
Carden˜a et al. [17].
Perthamide C reduced up to 96 h the expression of both NOS
isoforms i.e. eNOS and iNOS without affecting COXs expression
i.e. COX-1 and COX-2. This peculiar selectivity toward the two
enzymes deputed to produce NO lead us to investigate on a
possible action of perthamide C on lymphocytes infiltration and
activation that is typical of the second phase of this animal model.
Indeed, it is widely accepted that NO plays an important role in
immunomodulation and neutrophil trafficking [18,19]. In order to
be consistent, we approached this issue by studying the prolifer-
ation of PLN lymphocytes harvested from mice receiving in vivo
perthamide C. Lymphocytes challenged in vitro with Con A
displayed a reduced proliferation demonstrating that the effect of
perthamide C in vivo involves also these cellular population. This
result suggested a potential immuno-suppressor activity for
perthamide C.
In order to further investigate this effect a study was carried out
in vitro on lymphocytes recovered from naı¨ve mice. Surprisingly,
in contrast with the ex-vivo experiments, perthamide C added in
vitro to lymphocytes harvested from naı¨ve mice, did not modify
Con A-induced cellular proliferation at any of the concentrations
tested. Therefore, we hypothesized that perthamide C was most
likely subjected, in vivo, to a metabolic activation, probably at the
sulfate group on the Nd-carbamoyl-b-OSO3Asparagine unit, thus
acting as a pro-drug. Our assumption was confirmed by the
selective quantification of both metabolites by RP-HPLC-MSMS
analysis carried out on plasma samples collected at different time
points following each perthamide C administration in vivo to mice.
This hypothesis was confirmed by the finding that desulfated
perthamide C, namely perthamide H, did inhibit, in a concen-
tration-dependent manner, the Con A-induced proliferation of
lymphocytes harvested from naı¨ve mice as opposite to perthamide
C. The finding that perthamide C induces a state of immune-
suppression acting in vivo only after metabolic activation represents
an important outcome of our data since it give us a first insight into
a structure/activity relationship.
The marine environment has proven to be a very rich source of
extremely potent compounds that have demonstrated significant
activities in anti-tumor, anti-inflammatory, analgesia, immuno-
modulation, allergy and anti-viral assays. There are now
significant numbers of very interesting molecules that have come
from marine sources, or have been synthesized as a result of
knowledge gained from a prototypical compound, that are either
in or approaching Phase III clinical trials in cancer, analgesia and
allergy. In conclusion we have defined an immunomodulatory
activity of perthamide C in vivo and clarified that the action is due
to its metabolite Perthamide H. Therefore this cyclic peptide could
represent a new leading structure to develop therapeutics.
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